SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer

Cell Reports Medicine - Tập 3 - Trang 100502 - 2022
Meghan A. Rice1,2, Vineet Kumar3, Dhanir Tailor3,4,5, Fernando Jose Garcia-Marques1,2, En-Chi Hsu1,2, Shiqin Liu1,2, Abel Bermudez1,2, Vijayalakshmi Kanchustambham6, Vishnu Shankar6, Zintis Inde7, Busola Ruth Alabi1,2, Arvind Muruganantham1,2, Michelle Shen1,2, Mallesh Pandrala3,4,5, Rosalie Nolley8, Merve Aslan1,2, Ali Ghoochani1,2, Arushi Agarwal1,2, Mark Buckup1,2, Manoj Kumar1,2
1Department of Radiology, Stanford University, Stanford, CA 94305 USA
2Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA 94305, USA
3Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
4Department of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
5Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
6Department of Chemistry, Stanford University, Stanford, CA 94305 USA
7Department of Biology, Stanford University, Stanford, CA 94305, USA
8Department of Urology, Stanford University, Stanford, CA 94305, USA

Tài liệu tham khảo

Siegel, 2021, Cancer Statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N. Engl. J. Med., 367, 1187, 10.1056/NEJMoa1207506 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N. Engl. J. Med., 371, 424, 10.1056/NEJMoa1405095 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med., 364, 1995, 10.1056/NEJMoa1014618 Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J. Clin. Oncol., 26, 242, 10.1200/JCO.2007.12.4008 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Rathkopf, 2017, Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone, Clin. Cancer Res., 23, 3544, 10.1158/1078-0432.CCR-16-2509 Fizazi, 2019, Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer, N. Engl. J. Med., 380, 1235, 10.1056/NEJMoa1815671 Rice, 2019, Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer, Front. Oncol., 9, 801, 10.3389/fonc.2019.00801 Batovska, 2010, Trends in utilization of the pharmacological potential of chalcones, Curr. Clin. Pharmacol., 5, 1, 10.2174/157488410790410579 Dimmock, 1999, Bioactivities of chalcones, Curr. Med. Chem., 6, 1125, 10.2174/0929867306666220401182509 Kontogiorgis, 2005, Synthesis and antiinflammatory activity of coumarin derivatives, J. Med. Chem., 48, 6400, 10.1021/jm0580149 Going, 2018, Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer, J. Proteome Res., 17, 3574, 10.1021/acs.jproteome.8b00636 Zhang, 2017, A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells, Sci. Rep., 7, 9873, 10.1038/s41598-017-10400-3 Szliszka, 2009, Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells, Int. J. Mol. Sci., 11, 1, 10.3390/ijms11010001 Kim, 2012, Methoxychalcone inhibitors of androgen receptor translocation and function, Bioorg. Med. Chem. Lett., 22, 2105, 10.1016/j.bmcl.2011.12.141 Denmeade, 2002, A history of prostate cancer treatment, Nat. Rev. Cancer, 2, 389, 10.1038/nrc801 Knudsen, 2011, Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer, Expert Rev. Endocrinol. Metab., 6, 483, 10.1586/eem.11.33 Moses, 2018, Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer, Cancer Res., 78, 4022, 10.1158/0008-5472.CAN-17-3728 Nguyen, 2017, LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics, Prostate, 77, 654, 10.1002/pros.23313 Young, 2013, Establishment and serial passage of cell cultures derived from LuCaP xenografts, Prostate, 73, 1251, 10.1002/pros.22610 Saar, 2014, Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype, Cancer Lett., 351, 272, 10.1016/j.canlet.2014.06.014 Valta, 2016, Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer, Clin. Exp. Metastasis, 33, 325, 10.1007/s10585-016-9781-2 Rice, 2019, Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies, Mol. Cancer Ther., 18, 1230, 10.1158/1535-7163.MCT-18-0804 Hsu, 2020, Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1, Proc. Natl. Acad. Sci. USA, 117, 2032, 10.1073/pnas.1905384117 Maund, 2014, Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate, Lab. Invest., 94, 208, 10.1038/labinvest.2013.141 Savitski, 2014, Tracking cancer drugs in living cells by thermal profiling of the proteome, Science, 346, 1255784, 10.1126/science.1255784 Tailor, 2021, Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer, Cell Chem. Biol., 28, 1206, 10.1016/j.chembiol.2021.02.014 Bernstein, 1998, Crystal structures of substrates and products bound to the phosphoglycerate kinase active site reveal the catalytic mechanism, Biochemistry, 37, 4429, 10.1021/bi9724117 Banerjee, 2017, Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids, Proc. Natl. Acad. Sci. USA, 114, 3334, 10.1073/pnas.1700677114 Rajeshkumar, 2015, Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function, Cancer Res., 75, 3355, 10.1158/0008-5472.CAN-15-0108 Bok, 2019, The Role of Lactate Metabolism in Prostate Cancer Progression and Metastases Revealed by Dual-Agent Hyperpolarized 13C MRSI, Cancers (Basel), 11, 257, 10.3390/cancers11020257 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Pavlova, 2016, The Emerging Hallmarks of Cancer Metabolism, Cell Metab., 23, 27, 10.1016/j.cmet.2015.12.006 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Choi, 2018, Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer, Cancer Med., 7, 3385, 10.1002/cam4.1587 Eidelman, 2017, The Metabolic Phenotype of Prostate Cancer, Front. Oncol., 7, 131, 10.3389/fonc.2017.00131 Giunchi, 2019, The Metabolic Landscape of Prostate Cancer, Eur. Urol. Oncol., 2, 28, 10.1016/j.euo.2018.06.010 Sriram, 2020, Elevated Tumor Lactate and Efflux in High-grade Prostate Cancer demonstrated by Hyperpolarized 13C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures, Cancers (Basel), 12, 537, 10.3390/cancers12030537 Xiao, 2018, GLUT1 regulates cell glycolysis and proliferation in prostate cancer, Prostate, 78, 86, 10.1002/pros.23448 Akins, 2018, Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer, Curr. Top. Med. Chem., 18, 494, 10.2174/1568026618666180523111351 Dai, 2015, By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice, Oncotarget, 6, 13703, 10.18632/oncotarget.3800 Singh, 2018, Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate, Cancer Prev. Res. (Phila.), 11, 337, 10.1158/1940-6207.CAPR-17-0389 Pollyea, 2019, Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia, Leukemia, 33, 2575, 10.1038/s41375-019-0472-2 Mullard, 2017, FDA approves first-in-class cancer metabolism drug, Nat. Rev. Drug Discov., 16, 593, 10.1038/nrd.2017.196 Xiang, 2019, Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization, Cell Death Dis., 10, 40, 10.1038/s41419-018-1291-5 Xu, 2017, HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma, Mol. Cancer, 16, 178, 10.1186/s12943-017-0748-y Wagner, 2013, A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas, Clin. Cancer Res., 19, 6020, 10.1158/1078-0432.CCR-13-0953 Trepel, 2010, Targeting the dynamic HSP90 complex in cancer, Nat. Rev. Cancer, 10, 537, 10.1038/nrc2887 Oh, 2011, Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer, Urology, 78, 626, 10.1016/j.urology.2011.04.041 Thakur, 2016, A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study, Invest. New Drugs, 34, 112, 10.1007/s10637-015-0307-6 Tusher, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc. Natl. Acad. Sci. USA, 98, 10.1073/pnas.091062498 Navarro, 2014, General statistical framework for quantitative proteomics by stable isotope labeling, J. Proteome Res., 13, 1234, 10.1021/pr4006958 Tyanova, 2016, The Perseus computational platform for comprehensive analysis of (prote)omics data, Nat. Methods, 13, 731, 10.1038/nmeth.3901 Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 Echeverría, 2011, An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine, PLoS ONE, 6, e26044, 10.1371/journal.pone.0026044 Perez-Riverol, 2019, The PRIDE database and related tools and resources in 2019: improving support for quantification data, Nucleic Acids Res., 47, D442, 10.1093/nar/gky1106 Eberlin, 2011, Desorption electrospray ionization mass spectrometry for lipid characterization and biological tissue imaging, Biochim. Biophys. Acta, 1811, 946, 10.1016/j.bbalip.2011.05.006 Vijayalakshmi, 2020, Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging, Int. J. Cancer, 147, 256, 10.1002/ijc.32843